Hebbie Posted November 23, 2004 Share Posted November 23, 2004 FDA clears Genentech's Tarceva for lung cancer Deena Beasley Reuters Health Posting Date: November 19, 2004 Last Updated: 2004-11-19 10:08:34 -0400 (Reuters Health) LOS ANGELES (Reuters) - On Thursday, biotechnology companies Genentech Inc. and OSI Pharmaceuticals Inc. said U.S. regulators have approved their drug Tarceva for treating the most common form of lung cancer. The once-daily pill is designed to target human epidermal growth factor receptors and block them from allowing cancer cell growth. The FDA decision comes more than two months ahead of the agency's scheduled deadline. The U.S. regulatory approval applies to patients with locally advanced or metastatic non-small cell lung cancer who have failed at least one previous round of chemotherapy. Colin Goddard, OSI's chief executive, said Tarceva's wholesale price will be $2,026 for a 30-day supply, which is more expensive that Iressa, a targeted lung cancer drug sold by AstraZeneca Plc. "Ours is the only targeted epidermal growth factor receptor therapy to show a survival benefit," Goddard said. In a pivotal-stage trial, patients receiving Tarceva had a median survival of 6.7 months compared to 4.7 months in patients who received placebo. In addition, 31.2% of patients receiving Tarceva in the study were alive at one year versus 21.5% in the placebo arm. Side effects included rash and diarrhea. Goddard said the companies plan to file early next year for FDA approval of Tarceva as a treatment for pancreatic cancer. The drug is also being studied for a range of other cancers including ovarian and head and neck. South San Francisco, California-based Genentech and OSI, which is headquartered in Melville, New York, said Tarceva will be made available within five shipping days. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.